Optimizing diagnosis in Parkinson's disease: Radionuclide imaging.
Vancouver, Canada. In Parkinsonism Relat Disord, Jan 2016
Presynaptic dopaminergic dysfunction in PD can be revealed through the imaging of different steps in the process of dopamine synthesis and storage: L-aromatic amino acid decarboxylase (AADC) activity, Vesicular Monoamine Transporter type 2 (VMAT2) binding or its reuptake via the dopamine transporter (DAT).
Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours.
Uppsala, Sweden. In World J Gastroenterol, Jan 2016
METHODS: Control tissues from fundus (n = 3) and corpus (n = 3) mucosa of six patients undergoing operations for gastric adenocarcinoma, biopsy and/or gastric surgical specimens from 64 patients with primary gastric neuroendocrine tumours (GNETs), as well as metastases from 22 of these patients, were investigated using conventional immunohistochemistry and double immunofluorescence with commercial antibodies vs vesicular monoamine transporter 2 (VMAT-2), HDC and ghrelin.
Protein cysteine S-nitrosylation inhibits vesicular uptake of neurotransmitters.
Winnipeg, Canada. In Neuroscience, Jan 2016
In the central nervous system, vesicular monoamine transporter 2 (VMAT2) is responsible for the uptake of monoamines, vesicular acetylcholine transporter (VAChT) is responsible for the uptake of acetylcholine, while vesicular glutamate transporters 1 and 2 (VGLUT1 and VGLUT2) are responsible for the uptake of glutamate.
Brain dopamine-serotonin vesicular transport disease and its treatment.
Toronto, Canada. In N Engl J Med, 2013
We describe a disease encompassing infantile-onset movement disorder (including severe parkinsonism and nonambulation), mood disturbance, autonomic instability, and developmental delay, and we describe evidence supporting its causation by a mutation in SLC18A2 (which encodes vesicular monoamine transporter 2 [VMAT2]).
New insights into the mechanism of action of amphetamines.
Salt Lake City, United States. In Annu Rev Pharmacol Toxicol, 2006
Plasmalemmal and vesicular monoamine transporters, such as the neuronal dopamine transporter and the vesicular monoamine transporter-2, are two of its principal targets.